Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
KM

NASDAQ · KMDA

Kamada Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$8.08

Up+$0.31 (+3.92%)

Updated Oct 10, 2026, 2:47 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
405.5M
P/E ratio
20.98
Dividend yield
2.48%
52-week range
$6.85 – $9.11
Volume
72.77K
Avg. volume
76.93K

Price performance · KMDA

KMDA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

KMDA closed at $8.08 after 21 trading sessions, up 2.02% for the selected period.

Last close
$8.08
Period change
+2.02%
Period low
$7.78
Period high
$8.87
Daily close
View OHLC price history
KMDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$7.90$8.11$7.90$8.0872.77K
Oct 8, 2026$7.85$7.8516$7.682$7.77567.84K
Oct 7, 2026$7.92$7.9599$7.855$7.8972.84K
Oct 6, 2026$8.06$8.255$7.86$8.11147.2K
Oct 5, 2026$8.11$8.13$7.93$8.00137.51K
Oct 2, 2026$8.35$8.35$8.18$8.3157.88K
Oct 1, 2026$8.39$8.39$8.17$8.2093.66K
Sep 30, 2026$8.70$8.70$8.40$8.4699.01K
Sep 29, 2026$8.68$8.78$8.64$8.69548.34K
Sep 28, 2026$8.60$8.67$8.42$8.62147.95K
Sep 25, 2026$8.82$8.83$8.71$8.7292.05K
Sep 24, 2026$8.68$8.84$8.65$8.8387.32K
Sep 23, 2026$8.77$8.93$8.6945$8.77138.72K
Sep 22, 2026$8.71$8.91$8.68$8.87125.85K
Sep 21, 2026$8.90$8.96$8.73$8.74115.46K
Sep 18, 2026$8.75$8.88$8.68$8.85178.12K
Sep 17, 2026$8.41$8.75$8.41$8.67140.77K
Sep 16, 2026$8.21$8.29$8.10$8.19128.02K
Sep 15, 2026$8.17$8.19$7.995$8.09119.78K
Sep 14, 2026$8.082$8.361$8.05$8.31286.72K
Sep 11, 2026$8.05$8.11$7.90$7.92106.64K

Latest KMDA news

The latest Smart Investors Daily articles mentioning KMDA.

Stock researchCompany · Overview

KMDA research

Overview

Company profile and research snapshot.

Company profile

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
KMDA recent ratings
DateFirmRatingTarget
Dec 9, 2025HC Wainwright & Co.Buy—
May 15, 2025BenchmarkBuy—
Mar 21, 2025BenchmarkBuy—
Mar 6, 2025HC Wainwright & Co.Buy—
Jan 10, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 6, 2026

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-deriv

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By